Thus, the expected increase in monohexosylceramides derived from the deficiency of both β-GCase and β-gal activities observed in PD patients, might induce a rapid activation of CTSD, eventually resulting in the higher activity of the enzyme. The gene discussed is CTSD; the disease is Parkinson disease.